622368-88-1Relevant articles and documents
TREATMENT OF IMATINIB RESISTANT LEUKEMIA
-
, (2009/01/24)
The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.
4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML)
-
Page/Page column 28-29, (2010/02/11)
Compounds of the formula (I): wherein: n is an integer from 0-3; X is N, CH; R is alkyl of 1 to 3 carbon atoms; R' is 2,4-diCl, 5-OMe in para, ortho, or meta position; 2,4-diCl in para position; 3,4,5-tri-OMe in para position; 2-Cl, 5-OMe in para position
Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity
Boschelli, Diane H.,Ye, Fei,Wu, Biqi,Wang, Yanong D.,Barrios Sosa, Ana Carolina,Yaczko, Deanna,Powell, Dennis,Golas, Jennifer M.,Lucas, Judy,Boschelli, Frank
, p. 3797 - 3800 (2007/10/03)
Several 7-alkoxy-4-anilino-3-quinolinecarbonitriles were synthesized and evaluated for Src kinase inhibitory activity. Optimal inhibition of both Src enzymatic and cellular activity was seen with analogues having a 2,4-dichloro-5-methoxyaniline group at C-4. Compound 18, which has a 1-methylpiperidinemethoxy group at C-7, showed in vivo activity in a xenograft model.